Larimar Therapeutics, Inc.
LRMR
$0.03
Change (1 day)
$13.68
Year High
$3.01
Year Low
Categories
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
P/E ratio for Larimar Therapeutics, Inc. (LRMR)
P/E ratio as of 2023: -5.41
According to Larimar Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.41. At the end of 2022 the company had a P/E ratio of -3.11.
P/E ratio history for Larimar Therapeutics, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -5.41 |
| 2022 | -3.11 |
| 2021 | -3.68 |
| 2020 | -6.01 |
| 2019 | -5.31 |
| 2018 | -2.60 |
| 2017 | -2.44 |
| 2016 | -1.50 |
| 2015 | -2.27 |
| 2014 | -24.45 |
| 2013 | -36.80 |
| 2012 | -37.19 |
| 2011 | -39.23 |